Table 2.
Gene variant minor allele frequency (MAF) data obtained from West Virginia CRS clinic patients (N = 74) and public databases with demographically matched cohorts.
| Gene | dbSNP ID | Minor Allele | TaqMan Probe | European MAF* | MAF in CRS probands‡ |
|---|---|---|---|---|---|
| TAS2R38 | rs713598 | C | C___8876467_10 | 0.423 |
0.568 p < 0.001 |
| GNB3 | rs5443 | T | C___2184734_10 | 0.367 (HapMap#) |
0.493 p = 0.014 |
| TAS2R19 | rs10772420 | A | C___1317426_10 | 0.505 |
0.601 p = 0.024 |
| TAS2R20 | rs12226920 | T | C___1326611_10 | 0.383 | 0.458 p = 0.062 |
| RGS21 | rs7528947 | G | C__30007846_20 | 0.516 | 0.547 p = 0.461 |
| RGS21 | rs1175152 | A | C_____68684_10 | 0.433 | 0.439 p = 0.875 |
Minor allele frequency reported on N = 1006 Europeans via 1000 Genomes (#except as otherwise noted: i.e., 116 Europeans from HapMap); MAF comparisons between West Virginia probands and European SNP databases was previously established in Kaski, SW, et al. (2019) J. Opioid Manag. [in press; vol. 15, issue 1].
p-value denotes significance of difference between MAFs derived by comparison between CRS probands and European MAF using binomial test (null hypothesis is “no difference between CRS probands and Europeans”; alternative is “there is difference between CRS probands and Europeans”